Figure 4: VEGFR1 and VEGFR2 roles and changes in airway remodelling. | Scientific Reports

Figure 4: VEGFR1 and VEGFR2 roles and changes in airway remodelling.

From: The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease

Figure 4

(A) provided the data that moderately strong immunolabelling of VEGFR1 (brown) expressed in the epithelial cells of the respiratory vessels and a relatively lower level of VEGFR2 (brown) was discovered in the bronchial epithelial cells, capillary endothelial cells, and a small number of vascular smooth muscle cells (immunohistochemistry staining; original magnification ×200). (B) indicated a relative higher level of VEGFR1 in COPD rats compared the to normal rats and can be partly reversed with sunitinib. (C) showed a relative higher level of VEGFR2 in COPD rats, but sunitinib couldn’t inhibit it. (D,E) the concentration of VEGFR1 increased in BAL fluid and lung tissue in COPD rats and can be inhibited with sunitinib. (F,G) the level of VEGFR2 gained in the BAL fluid and lung tissue of both COPD groups (**P < 0.01, *P < 0.05, compared to the normal rats), (##P < 0.01, #P < 0.05, compared to the untreated COPD rats).

Back to article page